Trials / Withdrawn
WithdrawnNCT04055532
Biomarkers in Neurodegenerative Diseases
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
Conditions
- Mild Cognitive Impairment (MCI)
- Alzheimer Disease (AD)
- Dementia With Lewy Bodies (DLB)
- Frontotemporal Lobar Degeneration (FTLD)
- Parkinsons Disease With Dementia (PDD)
- Transient Epileptic Amnesia (TEA)
- Temporal Lobe Epilepsy (TLE)
- Spinocerebellar Ataxias (SCA)
- HIV Associated Neurocognitive Disorder (HAND)
- Amyotrophic Lateral Sclerosis (ALS)
- Primary Lateral Sclerosis (PLS)
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Neuraceq | Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2024-10-01
- Completion
- 2025-10-01
- First posted
- 2019-08-13
- Last updated
- 2019-11-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04055532. Inclusion in this directory is not an endorsement.